

Curriculum Vitae: Richard James Dillon

General Medical Council registration number: 6103271

Address: Cancer Genetics Lab, Floor 8 Tower Wing, Guy's Hospital, London SE1 9RT
Phone: 0207 848 2579 (office) / 07969 386998 (mobile)
Email: richarddillon@nhs.net (NHS) / richard.dillon@kcl.ac.uk (university)

Current Positions:

Group Leader and Clinical Senior Lecturer, Molecular Haematology Group.
Department of Medical and Molecular Genetics, King's College, London (appointed November 2016)

Consultant Haematologist, Acute Leukaemia and Haemato-Oncology Diagnostics
Guy's and St Thomas' NHS Foundation Trust, London (appointed May 2016)

Qualifications

2016	PhD	"The Biology of Acute Promyelocytic Leukaemia and Therapy-Related Myeloid Leukaemias"
2011	FRCPATH	Fellow of the Royal College of Pathologists of London
2008	MRCP (UK)	Member of the Royal College of Physicians of London
2004	MBBS	University of London (University College and Royal Free Medical School)
2001	BA	Physiological Science, University of Oxford, 1 st Class Honours

Grants Held

2020-2024. BlinAML – Blinatumomab for molecular relapse of AML with a t(8;21) translocation – investigator-initiated and sponsored phase II study. Amgen. £136,100

2020-2026. VICTOR – Venetoclax or Intensive Chemotherapy for Treatment of Favourable Risk Acute Myeloid Leukaemia: a molecularly guided randomised phase 2 study. CRUK. £942,171.81

2010-2021. The Clinical Development and Service Implementation of Molecular Monitoring to Direct Treatment of Acute Myeloid Leukaemia. D. Grimwade, R. Dillon, E. Solomon, B. Hunt. Programme Grant. NIHR. £2,680,042. (Costed extension of £282,726 awarded to R. Dillon for 2017-2021)

2016 – 2020. Understanding the Heterogeneity of Treatment Response in Standard Risk Acute Myeloid Leukaemia. R. Dillon (PI). Project Grant. Bloodwise. £320,486.

2016 – 2021. Molecular Tracking of Treatment Response in Paediatric AML. R. Dillon (PI). Project Grant. Children With Cancer. £238,324.

2019 – 2023. AMADEUS: A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects with Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation. C. Craddock (PI). £66,000 (KCL proportion).

2012 – 2015. Understanding the Origins of Acute Promyelocytic Leukaemia. R. Dillon, D. Grimwade, E. Solomon. Clinical Research Training Fellowship. Bloodwise. £262,834. (Now ended).

Employment

2012-2015	Leukaemia and Lymphoma Research Clinical Training Fellowship Department of Medical and Molecular Genetics, Kings College London Supervisors: Prof David Grimwade and Prof Ellen Solomon
2008-2012	Specialist Registrar in Haematology, Guys' and St Thomas' Hospitals, London
2007-2008	Core Medical Trainee, University College Hospital, London
2005-2007	Senior House Officer, Addenbrooke's Hospital, Cambridge

Professional commitments

KCL Cancer Genetics BSc programme	Module organiser
NCRI AML19 (phase 3 trial)	Lead for molecular diagnostics, MRD monitoring and APL.
CRUK MyeChild01 (phase 3 trial)	Lead for molecular diagnostics and MRD monitoring.
NCRI AML working group	Member, molecular MRD and APL lead.
ASH international consortium on AML	Member, co-chair of laboratory committee
European Leukaemia Net	Member, molecular MRD subgroup UK representative
Catapult WT01/02 (phase 1-2 trial)	Lead for molecular monitoring
Abbvie VIALE-M (phase 3 randomised trial)	UK Chief Investigator
CRUK VICTOR (phase 2 randomised trial)	Chief Investigator
Blood Cancer UK	Clinical Advisory Panel Member

Current Doctoral Student Supervision


William Villiers (year 4)	Co-supervisor with Cameron Osborne
Xaohan He (year 2)	Co-supervisor with Cameron Osborne
Leena Halim (year 3)	Co-supervisor with John Maher
Lena Boehme (year 4)	Member of Thesis Committee
Farrah Bakr (year 3)	Chair of Thesis Committee
Derrick Nebangwa (year 1)	Chair of Thesis Committee
Jad Othman (year 1)	Co-supervisor with Harry Iland

Publications

Please see KCL PURE (www.kcl.ac.uk/people/richard-dillon)

Invited presentations (2017-now)

West Midlands Acute Leukaemia Education Event (Birmingham UK)	25.04.17
Scottish Haematology Society: Annual Guest Lecture (Dunblane UK)	17.11.17
British Society of Haematology Annual Meeting: Education Programme (Liverpool UK)	17.04.18
West of Scotland Bone Marrow Transplant Education Programme (Glasgow UK)	01.06.18
UK NEQAS Annual Scientific Conference (Sheffield UK)	26.06.18
South West England Blood Club (Exeter UK)	04.10.18
Irish Haematology Association: Annual Guest Lecture (Dublin Ireland)	18.01.19
East of England Blood Club (Bury St Edmunds UK)	04.02.19
Yorkshire Bone Marrow Transplant Programme Annual Guest Lecture (Leeds UK)	17.05.19
University of Leicester Haematology Educational Programme (Leicester UK)	24.06.19
South Coast Acute Leukaemia Educational Event (Brighton UK)	25.06.19
Leeds Haematological Malignancy Diagnostic Service Annual Update (Leeds UK)	28.06.19
London Acute Leukaemia Educational Event (London UK) (Chair)	18.09.19
1 st National AML Academy (Birmingham UK)	19.09.19
Myanmar Medical Association Education Programme (Yangon, Myanmar)	21.09.19
UK Haematology Masterclass (chair of AML session)	14.02.20
2 nd National AML Academy (Birmingham UK)	08.10.20
Transplant Complications and GVHD (national educational event)	26.11.20
Current Thinking in Haematological Malignancies in 2020 (national educational event)	27.11.20
UK Haematology Masterclass (national educational event)	11.02.21



16th February 2021

Dr Richard Dillon

Clinical Senior Lecturer in Cancer Genetics, King's College London and Consultant Haematologist, Guy's and St Thomas' NHS Foundation Trust

Dr Richard Dillon is a Consultant Haematologist at Guy's Hospital and a Clinical Senior Lecturer in Cancer Genetics in the Department of Medical & Molecular Genetics at King's College London.

Dr Dillon's work is focussed on acute myeloid leukaemia, in particular the development of molecular diagnostics and molecularly targeted therapies. Dr Dillon contributes extensively to clinical trials in AML: he leads on molecular MRD for the UK NCRI AML trials and is currently the chief investigator of the VICTOR and BlinAML studies, which are investigating an MRD guided approach to therapy.